

# Ex-Chiral Pool Enaminones in the Synthesis of Functionalised Heterocycles<sup>†</sup>

Jurij Svete\*

Faculty of Chemistry and Chemical Technology, University of Ljubljana,  
1000 Ljubljana, Slovenia

Received October 2, 2003; accepted October 20, 2003  
Published online December 23, 2003 © Springer-Verlag 2003

**Summary.** Various chiral enaminones and hydrazones, derived from chiral pool starting materials, such as *L*-aspartic acid, *L*-3-phenylalanine, (+)-camphor, and *D*-aldoses were employed as key-intermediates in the synthesis of functionalised heterocycles, such as aminomethylidene substituted tetramic acids, heteroaryl substituted phenethylamines and terpenes, and *C*-nucleosides.

**Keywords.** Enaminones; Amino acids; Terpenes; Cyclisations; Nucleosides.

## Introduction


Due to their occurrence in nature, biological activity, and synthetic utility, there has been, in the last few decades, a significant interest for the synthesis of functionalised heterocyclic compounds, such as heteroarylalanines [1], peptidomimetics [2], and *C*-nucleosides [3]. The aim of our work in the field of functionalised heterocycles was to study synthetic methodologies for the preparation of heterocycles with an amino acid, hydroxy acid, amino alcohol, polyol, terpene, and related types of structural elements. Since our research interest is oriented towards various synthetic aspects of heterocyclic chemistry, we studied methodologies, which include formation of the heterocyclic part of the product as the key-step. Within our synthetic approaches towards functionalised heterocycles, enaminones, synthetic equivalents of 1,3-dicarbonyl compounds, represent the most frequently employed and versatile group of reagents [4]. In this connection, we have previously shown, that 2-substituted alkyl 3-(dimethylamino)propenoates **1** and related enaminones, including chiral cyclic analogs **2–5**, can serve as easily available and versatile reagents for the preparation of various heterocyclic systems and functionalised

---

\* Corresponding author. E-mail: jurij.svete@uni-lj.si

<sup>†</sup> Dedicated to Professor *Branko Stanovnik* on the occasion of his 65<sup>th</sup> anniversary

heterocyclic compounds [5]. For example, 3-heteroarylalanine derivatives were prepared by one step 'ring switching' transformations of pyrrolidones **2a**, **2b** with ambident nucleophiles [6–8]. In the same manner, some other related types of functionalised heterocycles, such as 3-heteroarylalaninol [9], 3-heteroaryllactic acid [10, 11], and 3-heteroarylpropane-1,2-diol derivatives [12] were obtained from the pyrrolidinone **3** and tetrahydrofuranones **4**, **5**. Chiral enaminones **2** and **4** were also used in the synthesis of heterocyclic analogs of dipeptides [4, 5, 13–16] (Fig. 1).



**Fig. 1.** Previous synthetic studies on chiral enaminones [4–16]




Fig. 2. Recent synthetic studies on chiral enaminones


In continuation of our research in this field, we have recently studied synthetic applications of enaminones **10–17**, which were prepared from  $L$ -aspartic acid (**6**),  $L$ -3-phenylalanine (**7**),  $N$ -glycylglycine (**8**), and (+)-camphor (**9**) (Fig. 2).

Studies on synthetic applicability of reagents **10–17** for the preparation of functionalised heterocycles are presented as the first two topics of this review. As the third topic, utilisation of  $D$ -aldose derived  $N$ -(heteroaryl)hydrazones in the synthesis of  $C$ -nucleosides is described.

### Syntheses with $\alpha$ -Amino Acid Derived Enaminones

#### *Preparation and Transformations of Benzyl (3*S*,4*E*)-4-[(Dimethylamino)methylidene]-5-oxotetrahydrofuran-3-ylcarbamate*

Benzyl (3*S*,4*E*)-4-[(dimethylamino)methylidene]-5-oxotetrahydrofuran-3-ylcarbamate (**10**) was synthesised in 4 steps from  $L$ -aspartic acid (**6**). First, tetrahydrofuranone **19** was prepared *via* transformation of **6** into the  $N$ -protected anhydride **18** followed by reduction and subsequent lactonisation according to literature procedures [17–19]. Lactone **19** was then treated with bis(dimethylamino)-*tert*-butoxymethane (*Bredereck's* reagent) to give **10** in 89% yield. Compound **10** was used in the parallel solution-phase synthesis of a library of twelve benzyl (3*S*,4*E*)-4-[(arylamino)methylidene]-5-oxotetrahydrofuran-3-ylcarbamates **21a–21l**. Upon



**Scheme 1.** Reagents and conditions: i)  $\text{ClCOOBn}$ ,  $\text{NaOH}$ ,  $\text{H}_2\text{O}$ ,  $0^\circ\text{C}$ ; ii)  $\text{Ac}_2\text{O}$ ,  $100^\circ\text{C}$ ; iii)  $\text{NaBH}_4$ ,  $\text{THF}$ ,  $0$ – $20^\circ\text{C}$ , then benzene, *p*- $\text{TsOH}$  (cat.), reflux (*Dean-Stark* apparatus); iv)  $t\text{-BuOCH}(\text{NMe}_2)_2$ , toluene,  $100^\circ\text{C}$ ; v)  $\text{ArNH}_2 \times \text{HCl}$  (**20a–20l**), 50% *EtOH* (aq.), rt

**Table 1.** Arylaminomethylidene substituted lactones **21a–21l**


| Compound   | <i>Ar</i>       | Yield/% | <i>E:Z</i> |
|------------|-----------------|---------|------------|
| <b>21a</b> | phenyl          | 89      | 93:7       |
| <b>21b</b> | 2-methylphenyl  | 45      | 81:19      |
| <b>21c</b> | 3-methylphenyl  | 76      | 96:4       |
| <b>21d</b> | 4-methylphenyl  | 88      | 93:7       |
| <b>21e</b> | 2-methoxyphenyl | 77      | 81:19      |
| <b>21f</b> | 3-methoxyphenyl | 62      | 87:13      |
| <b>21g</b> | 4-methoxyphenyl | 73      | 99:1       |
| <b>21h</b> | 2-bromophenyl   | 71      | 77:23      |
| <b>21i</b> | 3-bromophenyl   | 70      | 94:6       |
| <b>21j</b> | 4-bromophenyl   | 74      | 90:10      |
| <b>21k</b> | 3-hydroxyphenyl | 94      | 90:10      |
| <b>21l</b> | 4-hydroxyphenyl | 46      | 100:0      |

addition of aqueous solutions of aniline hydrochlorides **20a–20l** to an ethanolic solution of reagent **10**, stirring at room temperature, filtration of the precipitated products, washing, and thorough drying, the corresponding dimethylamine substituted products **21a–21l** were obtained in 45–94% yields, in most cases in analytically pure form. Compounds **21a–21k** were isolated as mixtures of the major (*E*)-isomers and the minor (*Z*)-isomers, while compound **21l** was isolated as pure (*E*)-isomer [20] (Scheme 1, Table 1).

*Preparation and Transformations of 2-Substituted 1-Acyl-4-[(E)-(dimethylamino)methylidene]pyrrolidin-3,5-diones and (S)-1-Acylamino-1-benzyl-4-diethylamino-2-oxobut-3-enes*

The second type of chiral enaminones, which we used within our recent studies, are 4-(dimethylamino)methylidene substituted tetramic acids **11–13**. The first two

model reagents, **11** and **12**, were obtained from the *N*-protected *L*-3-phenylalanines **22** and **23**, which were first transformed into the corresponding (*S*)-1-acyl-2-benzyltetramic acids **24** and **25** according to literature procedures [21]. Treatment of compounds **24** and **25** with *N,N*-dimethylformamide dimethyl acetal (*DMFDMA*) gave the desired enaminones **11** and **12** in 91 and 89% yield, respectively. This method for preparation of enamino tetramic acids enables variation of substituents at positions 1 and 2 by suitable choice of *N*-protected  $\alpha$ -amino acids and peptides as starting materials. In order to confirm these possible variations, 4-[(dimethylamino)methylidene]pyrrolidine-3,5-dione **13** with a glycine residue attached at the position 1 was prepared from *N*-(*N*-benzyloxycarbonylglycyl)glycine (**8**) in 65% overall yield according to the previously established procedure for the preparation of **11** and **12**. With all three enaminones **11**–**13** a series of dimethylamine substitution reactions was carried out with primary aliphatic amines and amino acid esters, as well as with aromatic and heteroaromatic amines. NMR structural studies




**Scheme 2.** Reagents and conditions: i) Meldrum's acid, *DCC*, *DMAP*,  $CH_2Cl_2$ , 0–20°C; ii) *EtOAc*, reflux; iii) *DMFDMA*, toluene or  $CH_2Cl_2$ , 45–80°C; iv)  $R^3NH_2 \times HCl$ , *EtOH*, 20–80°C

**Table 2.** 4-Aminomethylidene substituted tetramic acids **26–28**

| Compound        | $R^3$  | Yield/%   |           |           |
|-----------------|--|-----------|-----------|-----------|
|                 |  | <b>26</b> | <b>27</b> | <b>28</b> |
| <b>26a–28a</b>  | $\text{CH}_2\text{COOMe}$  | 88        | 75        | 35        |
| <b>26b</b>      | $\text{CH}(\text{Me})\text{COOEt}$ ( <i>S</i> )                          | 95        |           |           |
| <b>26c, 27c</b> | $\text{CH}(\textit{i-Pr})\text{COOMe}$ ( <i>S</i> )                      | 89        | 93        |           |
| <b>28d</b>      | $\text{CH}(\text{CH}_2\text{Ph})\text{COOMe}$ ( <i>S</i> )               | 88        |           |           |
| <b>26e</b>      | $\text{CH}(\text{CH}_2\text{CH}_2\text{COOEt})\text{COOEt}$ ( <i>S</i> ) | 84        |           |           |
| <b>26f, 27f</b> | $\text{CH}(\text{CH}_2\text{SH})\text{COOEt}$ ( <i>S</i> )               | 90        | 46        |           |
| <b>26g</b>      | $\text{CH}_2\text{CH}_2\text{COOEt}$                                     | 95        |           |           |
| <b>28h</b>      | 1-adamantyl  |           |           | 51        |
| <b>26i–28i</b>  | <i>Ph</i>  | 87        | 83        | 92        |
| <b>28j</b>      | 2-methoxyphenyl  |           |           | 84        |
| <b>28k</b>      | 3-methoxyphenyl  |           |           | 86        |
| <b>28l</b>      | 4-methoxyphenyl  |           |           | 83        |
| <b>28m</b>      | 2-bromophenyl  |           |           | 83        |
| <b>28n</b>      | 3-bromophenyl  |           |           | 86        |
| <b>28o</b>      | 4-bromophenyl  |           |           | 90        |
| <b>26p–28p</b>  | 4-nitrophenyl  | 68        | 79        | 83        |
| <b>28q</b>      | phenylene-1,4-diyl   |           |           | 95        |
| <b>28r</b>      | 1-naphthyl   |           |           | 79        |
| <b>26s, 28s</b> | pyridin-2-yl   | 63        |           | 33        |
| <b>28t</b>      | quinolin-3-yl  |           |           | 89        |
| <b>26u</b>      | pyrimidin-2-yl   | 63        |           |           |
| <b>26v–28v</b>  | pyrazinyl  | 76        | 94        | 25        |
| <b>28w</b>      | indazol-3-yl   |           |           | 89        |
| <b>26x</b>      | isoxazol-3-yl  | 63        |           |           |
| <b>26y</b>      | 5-methylisoxazol-3-yl  | 48        |           |           |
| <b>27z</b>      | tetrazolyl   |           | 74        |           |

showed, that the dimethylamine substitution products **26–28** exist in solution as the major (*Z*)-isomers and the minor (*E*)-isomers, while reagents **11–13** exist as single (*E*)-isomers. The structure of **11** was additionally confirmed by X-ray diffraction [22] (Scheme 2, Table 2).


Further investigations were oriented towards the substitution of the dimethylamino group in the enaminones with *Grignard* reagents. The *N*-glycylglycine derived enaminone **13** was chosen for this purpose. In the first experiment, treatment of **13** with an excess of phenylmagnesium bromide afforded the expected substitution product **29** in 27% yield. On the other hand, upon treatment of enaminone **13** with an excess of ethynylmagnesium bromide, 1-benzyloxycarbonylamino-4-dimethylamino-2-oxobut-3-ene (**32**) was isolated in 50% yield. A possible explanation for formation of enaminone **32** could be, that ethynylmagnesium bromide apparently reacted at two sites: a) at the methylidene group leading to substitution of the dimethylamino group, releasing one equivalent of dimethylamine and b) at the carbonyl group of the glycine residue attached to position 1. The so formed acetylenic ketone **31** then reacts with dimethylamine



**Scheme 3.** Reagents and conditions: i)  $PhMgBr$  (5 equiv),  $THF$ ,  $-78^\circ C \rightarrow rt$ , then  $NH_4Cl$  (aq.); ii)  $HC\equiv CMgBr$  (5 equiv),  $THF$ ,  $-78^\circ C \rightarrow rt$ , then  $NH_4Cl$  (aq.)

to give enaminone **32** [22]. This proposed way of formation of the enaminone **32** is supported also by analogous examples from the literature, *e.g.* synthesis of  $\alpha$ -amino ketones from *N*-protected  $\alpha$ -amino acids *via* transformation into the Weinreb amides followed by reaction with *Grignard* reagents including the acetylenic ones [23] (Scheme 3).

Since, to the best of our knowledge, there are no literature reports on utilization of acyclic chiral enaminone ketones, such as enaminone **32**, in the synthesis of functionalised heterocycles, we decided to prepare two model reagents of this type in order to study their reactivity and possible synthetic applications. The *N*-protected *L*-3-phenylalanines **22** and **23** were transformed into the corresponding ketones **33** and **34** according to the literature procedure [24]. Addition of diethylamine to ethynyl ketones **33** and **34** gave enaminones **35** and **36**. It has to be mentioned, that compounds **35** and **36** are just the model reagents; the method for their preparation also enables the use of other *N*-protected  $\alpha$ -amino acids as starting materials and, consequently, the introduction of other substituents of position 1. So far, only preliminary tests have been done in connection with synthetic applications of reagents **35** and **36**. Cyclocondensation reactions with hydrazines,



**Scheme 4.** Reagents and conditions: i)  $ClCOOBu$ ,  $CH_2Cl_2$ ,  $-15^\circ C$ ; ii)  $NHMeOMe \times HCl$ ,  $Et_3N$ ,  $CH_2Cl_2$ ,  $0-20^\circ C$ ; iii)  $HC\equiv CMgBr$  (5 equiv),  $THF$ ,  $-78^\circ C \rightarrow rt$ , then  $NH_4Cl$  (aq.); iv)  $Et_2NH$ ,  $EtOH$ , rt; v)  $R^2NHNH_2 \times HCl$ ,  $EtOH$ , reflux; vi) benzamidinium hydrochloride,  $K_2CO_3$ ,  $EtOH$ , reflux; vii) 3-aminopyrazole hydrochloride or 3-aminopyrazole-4-carbonitrile hydrochloride,  $EtOH$ , rt

**Table 3.** *N*-Acyl-1-heteroaryl-2-phenylethylamines **37–41**

| Compound   | $R^1$        | $R^2$                  | Yield/% |
|------------|--------------|------------------------|---------|
| <b>37a</b> | <i>Ot-Bu</i> | H                      | 84      |
| <b>37b</b> | <i>Ot-Bu</i> | 2-bromophenyl          | 85      |
| <b>37c</b> | <i>Ot-Bu</i> | 6-chloropyridazin-3-yl | 52      |
| <b>38c</b> | <i>OBn</i>   | 6-chloropyridazin-3-yl | 91      |
| <b>39</b>  |              |                        | 27      |
| <b>40a</b> | <i>Ot-Bu</i> | H                      | 44      |
| <b>40b</b> | <i>Ot-Bu</i> | CN                     | 20      |
| <b>41a</b> | <i>OBn</i>   | H                      | 67      |


amidines, and aminoazoles as ambident nucleophiles furnished the corresponding 1-heteroaryl-2-phenylethylamines **37–41** [22] (Scheme 4, Table 3).

### Synthesis with (+)-Camphor Derived Enaminones

In continuation, our work was extended also on (+)-camphor (**9**) derived enaminones. In this series, two reagents were prepared: (1*R*,4*R*)-3-[(*E*)-(dimethylamino)



methylidene]-1,7,7-trimethylbicyclo[2.2.1]heptan-2-one (**16**) and (1*R*,5*S*)-4-[(*E*)-(dimethylamino)methylidene]-1,8,8-trimethyl-2-oxabicyclo[3.2.1]octan-3-one (**17**). Compound **16** has been prepared for the first time almost hundred years ago by *Staudinger* and *Kon* in 2 steps via the 3-formylcamphor followed by condensation with dimethylamine [25]. However, we prepared enaminone **16** in one step from (+)-camphor (**9**) and *Bredereck's* reagent [26]. Reagent **17** was prepared in 2 steps. First, (+)-camphor (**9**) was transformed into the lactone **42** by *Baeyer-Williger* oxidation according to the literature procedure [27], followed by treatment with *Bredereck's* reagent to give the enamino lactone **17** [28]. Also with enaminones **16** and **17** a series of substitution reactions was carried out with various primary amines including  $\alpha$ -amino acid esters, as well as with *C*-nucleophiles, such as 2-methylindole, potassium



**Scheme 5.** Reagents and conditions: i) *t*-BuOCH(NMe<sub>2</sub>)<sub>2</sub>, DMF, reflux; ii) AcOOH, AcOH, AcONa, rt; iii) *t*-BuOCH(NMe<sub>2</sub>)<sub>2</sub>, decaline, reflux; iv) RNH<sub>2</sub> × HCl, EtOH, reflux; v) 2-methylindole, HCl, EtOH, reflux; vi) KCN, AcOH, rt; vii) RMgBr (5 equiv), THF, -78°C → rt, then NH<sub>4</sub>Cl (aq.)

cyanide, and *Grignard* reagents. Substitution products **43** and **44**, obtained upon reactions of **16** and **17** with primary amines, exist in solution as mixtures of the major (*Z*)-isomers and the minor (*E*)-isomers, whereas reagents **16** and **17** and substitution products **45–49**, obtained upon reactions with *C*-nucleophiles, exist as single (*E*)-isomers. In the case of both reagents, **16** and **17**, and several products obtained by substitution of the dimethylamino group, the configuration around the exocyclic C=C bond was determined by X-ray diffraction, as well as by NMR using NOESY and HMBC techniques [26, 28] (Scheme 5, Table 4).


Cyclocondensation reactions were studied with various substituted hydrazines. Reactions of **16** with hydrazines **50a–50c** furnished 3,4-diazatricyclo[5.2.1.0<sup>2,6</sup>]

**Table 4.** (+)-Camphor derived enaminones **16** and **17** and products obtained by substitution of the dimethylamino group **43–49**

| Compound        | <i>R</i>   | Yield/% |
|-----------------|--|---------|
| <b>16</b>       |  | 43      |
| <b>17</b>       |  | 44      |
| <b>43a, 44a</b> | CH <sub>2</sub> CN   | 81, 34  |
| <b>43b, 44b</b> | CH <sub>2</sub> COOMe  | 76, 40  |
| <b>43c, 44c</b> | CH <sub>2</sub> CH <sub>2</sub> COOEt                                      | 54, 30  |
| <b>43d, 44d</b> | CH(CH <sub>2</sub> CH <sub>2</sub> COOEt)COOEt ( <i>S</i> )                | 54, 41  |
| <b>44e</b>      | CH( <i>Me</i> )COOEt ( <i>S</i> )  | 36      |
| <b>44f</b>      | CH[CH(OH) <i>Me</i> ]COOEt ( <i>S</i> )                                    | 55      |
| <b>44g</b>      | CH(CH <sub>2</sub> <i>Ph</i> )COOMe ( <i>S</i> )                           | 43      |
| <b>44h</b>      | CH[CH <sub>2</sub> (4-HO-C <sub>6</sub> H <sub>4</sub> )COOMe ( <i>S</i> ) | 64      |
| <b>44i</b>      | CH(1 <i>H</i> -indol-3-yl)COOMe ( <i>S</i> )                               | 36      |
| <b>44j</b>      | (1-adamantyl)methyl  | 43      |
| <b>44k</b>      | propargyl  | 68      |
| <b>44l</b>      | <i>Ph</i>  | 67      |
| <b>44m</b>      | 4-methylphenyl   | 41      |
| <b>44n</b>      | 4-methoxyphenyl  | 29      |
| <b>44o</b>      | 4-nitrophenyl  | 44      |
| <b>44p</b>      | 2-aminophenyl  | 63      |
| <b>44q</b>      | 4-hydroxyphenyl  | 59      |
| <b>44r</b>      | quinolin-3-yl  | 69      |
| <b>44s</b>      | pyrazinyl  | 41      |
| <b>44t</b>      | indazol-3-yl   | 35      |
| <b>44u</b>      | [1,2,4]-1 <i>H</i> -triazol-3-yl   | 52      |
| <b>45</b>       |  | 84      |
| <b>46</b>       |  | 14      |
| <b>47</b>       |  | 31      |
| <b>48</b>       |  | 49      |
| <b>49a</b>      | <i>Me</i>  | 71      |
| <b>49b</b>      | <i>Et</i>  | 83      |
| <b>49c</b>      | <i>n-Bu</i>  | 68      |
| <b>49d</b>      | benzyl   | 67      |
| <b>49e</b>      | <i>Ph</i>  | 89      |
| <b>49f</b>      | ethynyl  | 35      |

deca-2(6),4-dienes **52a–52c** in 63–83% yields. On the other hand, from lactone **17** and hydrazines **50a** and **50d–50j**, two types of products were formed, 7-oxa-4,5-diazatricyclo[6.2.1.0<sup>2,6</sup>]undeca-2(6),3-dienes **55d–55f** and pyrazolones **56a** and **56g–56j**. Formation of both types of products can be explained by initial substitution of the dimethylamino group to give the enehydrazine **53** followed by addition of the second amino group to the lactone carbonyl group. From the intermediate **54**, elimination reaction can occur, either by elimination of water leading to pyrazolo fused lactones **55** (Path A), or by elimination of the alcohol moiety (opening of the lactone ring) leading to ‘ring switched’ pyrazolones **56** (Path B). This explanation is also in agreement with formation of hydroxy and alkoxy pyrazoles from hydrazines and  $\beta$ -keto esters [29]. Selectivity was dependent on the substituents attached to the hydrazino group. With *ortho*-unsubstituted phenylhydrazines **50d–50f** fused pyrazoles **55d–55f** were formed, whereas from hydrazine hydrochloride (**50a**) and *ortho*-substituted phenylhydrazines **50g–50j** the pyrazolones **56a** and **56g–56j** were obtained [28] (Scheme 6, Table 5).

Enaminone **16** was also employed in one-pot stereoselective syntheses of (1*R*,3*R*,4*R*)-3-(1,2,4-triazolo[4,3-*x*]azin-3-yl)-1,7,7-trimethylbicyclo[2.2.1]heptan-2-ones **60a–60g**. Treatment of **16** with  $\alpha$ -hydrazinoazines **57a–57g** followed by oxidative cyclisation with methanolic bromine and chromatographic purification afforded, stereoselectively, the *endo*-isomers of 3-heteroarylcamphors **60a–60g** in 37–79% yields and in 68–94% d.e. Isomerically pure or isomerically enriched compounds **60a–60g** were obtained upon crystallisation. This one pot




**Scheme 6.** Reagents and conditions: i) RNHNH<sub>2</sub> × HCl **50a–50c**, MeOH or AcOH, reflux; ii) RNHNH<sub>2</sub> × HCl **50a, 50d–50j**, *n*-PrOH, reflux

**Table 5.** Cyclocondensation products **52**, **55**, and **56**

| Compound                | R                       | Yield/%   |           |           |
|-------------------------|-------------------------|-----------|-----------|-----------|
|                         |                         | <b>52</b> | <b>55</b> | <b>56</b> |
| <b>52a</b> , <b>56a</b> | H                       | 81        |           | 83        |
| <b>52b</b>              | benzyl                  | 63        |           |           |
| <b>52c</b>              | 6-hydroxypyridazin-3-yl | 83        |           |           |
| <b>55d</b>              | <i>Ph</i>               |           | 91        |           |
| <b>55e</b>              | 3-methylphenyl          |           | 74        |           |
| <b>55f</b>              | 4-methylphenyl          |           | 85        |           |
| <b>56g</b>              | 2-methylphenyl          |           |           | 70        |
| <b>56h</b>              | 2-chlorophenyl          |           |           | 61        |
| <b>56i</b>              | 2-bromophenyl           |           |           | 63        |
| <b>56j</b>              | perfluorophenyl         |           |           | 56        |









transformation proceeds by initial substitution of the dimethylamino group to give the enehydrazines **58** which tautomerise into the hydrazone forms **59** and **59'**. Further oxidative cyclisation of hydrazones **59/59'** leads to 1,2,4-triazolo[4,3-*x*]azine derivatives **60a–60g** [26] (Scheme 7, Table 6).

Similar treatment of **17** with  $\alpha$ -hydrazinoazines **57a–57e** followed by oxidative cyclisation with lead tetraacetate led to two types of products, 1,2,4-triazolo[4,3-*x*]azine derivatives **63a–63e** and diazenes **64a–64e**. In the pyridazine series, 1,2,4-triazolo[4,3-*b*]pyridazines **63b** and **63c** were the major products, whereas



**Scheme 7.** Reagents and conditions: i) *MeOH*, 37% *HCl* (aq., 1 equiv), rt; ii)  $\text{Br}_2$ , *MeOH*, rt, then chromatographic purification


**Table 6.** 1,2,4-Triazolo[4,3-*x*]azines **60a–60g**

| Compound   |    | D.e./% | Yield/% |
|------------|---|--------|---------|
| <b>60a</b> |    | 68     | 37      |
| <b>60b</b> |    | 84     | 79      |
| <b>60c</b> |    | 94     | 71      |
| <b>60d</b> |    | 84     | 42      |
| <b>60e</b> |    | 72     | 59      |
| <b>60f</b> |   | 94     | 60      |
| <b>60g</b> |  | 92     | 61      |

predominant formation of diazenes **64a**, **64d**, and **64e** took place in the other three cases [28] (Scheme 8, Table 7).

Further transformations of 3-heteroarylcamphors **60b–60e** were also studied. Catalytic hydrogenation of **60c–60e** under 50 bars of hydrogen resulted in saturation of the six-membered ring to give the tetrahydro analogues **65c–65e** in 73–93% yields. Bromination of **60b** in dichloromethane gave two isomeric  $\alpha$ -bromination products **66** and **67** in 44 and 43% yield, respectively. Unfortunately,  $\alpha$ -bromination was not stereoselective, since both isomers, **66** and **67**, were formed in 1:1 ratio. Isomers **66** and **67** were separated by medium pressure liquid chromatography (MPLC) and both structures were determined by X-ray analysis [28] (Scheme 9).


Upon treatment of compounds **60a–60c** and **60g** with borane–methylsulfide in dichloromethane under reflux, stable complexes with borane **68a–68c** and **68g** were obtained in 29–58% yields. X-Ray diffraction analysis of **68b** showed, that complexation of borane occurs at the N-1 in the 1,2,4-triazolo[4,3-*x*]azinyl residue.



**Scheme 8.** Reagents and conditions: i) MeOH, 97% H<sub>2</sub>SO<sub>4</sub> (1 equiv), rt; ii) Pb(OAc)<sub>4</sub>, CH<sub>2</sub>Cl<sub>2</sub>, rt, then chromatographic separation

**Table 7.** 1,2,4-Triazolo[4,3-*x*]azines **63a–63e** and diazenes **64a–64e**

| Compound        |  |  | D.e./%    |  | Yield/%   |           |
|-----------------|--|--|-----------|--|-----------|-----------|
|                 |  |  | <b>63</b> |  | <b>63</b> | <b>64</b> |
| <b>63a, 64a</b> |  |  | 66        |  | 11        | 50        |
| <b>63b, 64b</b> |  |  | 94        |  | 52        | 10        |
| <b>63c, 64c</b> |  |  | 90        |  | 46        | 29        |
| <b>63d, 64d</b> |  |  | 54        |  | 4         | 54        |
| <b>63e, 64e</b> |  |  | 70        |  | 6         | 42        |




**Scheme 9.** Reagents and conditions: i)  $\text{H}_2$  (50 bar), 10% Pd-C, *EtOH*,  $50^\circ\text{C}$ ; ii)  $\text{Br}_2$ ,  $\text{CH}_2\text{Cl}_2$ , rt; iii) chromatographic separation (MPLC)

On the other hand, activation of **60a–60c** and **60g** with 1 equivalent of boron trifluoride etherate followed by treatment with borane–methylsulfide and thorough chromatographic purification furnished the corresponding isoborneols **69a–69c** and **60g** in 39–62% yields. Upon treatment of isoborneols **69b** and **69g** with borane–methylsulfide in refluxing dichloromethane, complexes **70b** and **70g** were obtained in 23 and 10% yield, respectively [28] (Scheme 10, Table 8).

### Synthesis of C-Nucleosides from D-Aldose Derived Hydrazones

We have previously shown, that commercially available unprotected aldoes **71** can be transformed with  $\alpha$ -hydrazinoazines **57** into the 1-(1,2,4-triazolo[4,3-*x*]azin-3-yl)polyols **73** using a 2 step one-pot protocol, which includes formation of aldose (*N*-aziny)hydrazones **72** followed by oxidative cyclisation with methanolic bromine [30]. Similarly, cyclic *O*-protected analogs **79–83** were prepared from suitably protected aldehyde sugars **74–78** [30, 31] (Scheme 11).

Acetonisation of *D*-glucose derived arabinitol **73a** led to a mixture of two regioisomeric bis-ketals **84** and **85**, which were separated by MPLC or crystallization. Acetonisation of *D*-mannose derived arabinitol **73b** led regioselectively to 2,3:5,6-di-*O*-isopropylidene-*D*-arabinitol **86**. In order to carry out transformation




**Scheme 10.** Reagents and conditions: i)  $\text{BH}_3 \times \text{Me}_2\text{S}$ ,  $\text{CH}_2\text{Cl}_2$ , reflux; ii)  $\text{BF}_3 \times \text{Et}_2\text{O}$ ,  $\text{CH}_2\text{Cl}_2$ ,  $0^\circ\text{C}$ ; iii)  $\text{BH}_3 \times \text{Me}_2\text{S}$ ,  $\text{CH}_2\text{Cl}_2$ ,  $0-20^\circ\text{C}$ ; iv) chromatographic separation: first column chromatography followed by medium pressure liquid chromatography (MPLC)

**Table 8.** Borane-1,2,4-triazolo[4,3-*x*]azines **68a–68c**, **68g**, **70b**, and **70g** and isoborneols **69a–69c**, and **69g**


| Compound        |  | Yield/%   |           |           |
|-----------------|--|-----------|-----------|-----------|
|                 |  | <b>68</b> | <b>69</b> | <b>70</b> |
| <b>68a, 69a</b> |  | 58        | 58        |           |
| <b>68b–70b</b>  |  | 58        | 62        | 23        |
| <b>68c, 69c</b> |  | 29        | 57        |           |
| <b>68g–70g</b>  |  | 34        | 39        | 10        |





**Scheme 11.** Reagents and conditions: i)  $\alpha$ -hydrazinoazine **57**, MeOH, 37% HCl (aq., cat.), rt-reflux; ii) Br<sub>2</sub>, MeOH, rt; iii) Pb(OAc)<sub>4</sub>, CH<sub>2</sub>Cl<sub>2</sub>, rt

of bis-ketals **85** and **86** into *C*-nucleosides **89** and **90**, a slightly modified synthetic protocol, reported previously by *Buchanan et al.* [32], was employed. Thus, compounds **85** and **86** were mesylated and the mesylates **87** and **88** were then heated in dimethoxyethane in the presence of 1 equivalent of 4% hydrochloric acid to afford 3-( $\alpha$ -*D*-arabinofuranosyl)-6-chloro-1,2,4-triazolo[4,3-*b*]pyridazine (**89**) and its  $\beta$ -anomer **90** in 81 and 54% yield, respectively. The  $\beta$ -anomer **90** was obtained in the form of its HCl salt and its structure was determined by X-ray diffraction [33] (Scheme 12).



**Scheme 12.** Reagents and conditions: i) acetone, 97% H<sub>2</sub>SO<sub>4</sub>, rt; ii) chromatographic separation or crystallisation; iii) MeSO<sub>2</sub>Cl (MsCl), pyridine, 0°C; iv) 1,2-dimethoxyethane, 4% HCl (aq., 1 equiv), reflux

## Acknowledgements

At the end, I would like to express my sincere gratitude to all of them who made this lecture possible, especially to Professor Dr. *Branko Stanovnik*, the head of our research group, for a fruitful collaboration, permanent support, and scientific guidance; then to *Uroš Grošelj*, *Samo Pirc*, *Martin Šala*, and other members of our group for their enthusiastic, skillful, and dedicated work. Many thanks are due to *David Bevk*, *Renata Jakše*, Dr. *Simon Rečnik*, and Dr. *Simona Golič Grdadolnik*, for NMR studies and to Professor Dr. *Ljubo Golič*, Dr. *Amalija Golobič*, and Professor Dr. *Anton Meden* for the X-ray structural determinations. From the financial point of view, this research was enabled by the support from the Ministry of Education, Science and Sport, Slovenia, Krka d.d., and Lek d.d., Slovenia. Many thanks are also due to the Alexander von Humboldt-Stiftung, Germany, for the donation of a medium pressure liquid chromatograph.

## References

- [1] Kolar P, Petrič A, Tišler M (1997) *J Heterocyclic Chem* **34**: 1067
- [2] Hanessian S, McNaughton-Smith G, Lombart H-G, Lubell WD (1997) *Tetrahedron* **53**: 12789
- [3] For some reviews see: a) Lamberth C (2002) *Org Prep Proced Int* **34**: 149; b) Shaban MAE, Nasr AZ (1997) *Adv Heterocycl Chem* **68**: 223; c) Shaban MAE (1998) *Adv Heterocycl Chem* **70**: 163; d) Knutsen LJS (1992) *Nucleosides, Nucleotides* **11**: 961; e) Chu CK, Cutler SJ (1986) *J Heterocyclic Chem* **23**: 289
- [4] Svete J (2002) *J Heterocyclic Chem* **39**: 437
- [5] For recent reviews see: a) Stanovnik B, Svete J (2000) *Targets in Heterocyclic Systems* **4**: 105; b) Stanovnik B, Svete J (2000) *Synlett*: 1077; c) Stanovnik B (1999) *J Heterocyclic Chem* **36**: 1581
- [6] Škof M, Svete J, Stanovnik B (1999) *Heterocycles* **51**: 1051
- [7] Škof M, Svete J, Stanovnik B (2000) *Heterocycles* **53**: 339
- [8] Škof M, Svete J, Stanovnik B, Golič Grdadolnik S (1999) *Acta Chim Slov* **46**: 567
- [9] Škof M, Svete J, Stanovnik B, Golič Grdadolnik S (2000) *Helv Chim Acta* **83**: 760
- [10] Škof M, Svete J, Stanovnik B (2000) *Heterocycles* **52**: 845
- [11] Škof M, Svete J, Stanovnik B (2000) *J Heterocyclic Chem* **37**: 703
- [12] Mihelič D, Jakše R, Svete J, Stanovnik B, Golič Grdadolnik S (2001) *J Heterocyclic Chem* **38**: 1307
- [13] Škof M, Svete J, Stanovnik B, Golič L, Golič Grdadolnik S, Selič L (1998) *Helv Chim Acta* **81**: 2332
- [14] Škof M, Svete J, Kmetič M, Golič Grdadolnik S, Stanovnik B (1999) *Eur J Org Chem*: 1581
- [15] Pirc S, Rečnik S, Škof M, Svete J, Golič L, Meden A, Stanovnik B (2002) *J Heterocyclic Chem* **39**: 411
- [16] Škof M, Pirc S, Rečnik S, Svete J, Stanovnik B, Golič L, Selič L (2002) *J Heterocyclic Chem* **39**: 957
- [17] Bergmann M, Zervas L (1932) *Chem Ber* **65**: 1192
- [18] Lutz WB, Ressler C, Nettleton DE Jr, Du Vigneaud V (1959) *J Am Chem Soc* **81**: 167
- [19] McGarvey GJ, Williams JM, Hiner RN, Matsubara Y, Oh T (1986) *J Am Chem Soc* **108**: 4943
- [20] Pirc S, Bevk D, Golič Grdadolnik S, Svete J (2003) *Arkivoc* (xiv): 37
- [21] a) Jouin P, Castro B, Nisato D (1987) *J Chem Soc Perkin Trans 1*: 1177; b) Courcambeck J, Bihel F, De Michelis C, Quelever G, Kraus JL (2001) *J Chem Soc Perkin Trans 1*: 1421
- [22] Pirc S, Svete J, Stanovnik B: to be published
- [23] Sibi MP (1993) *Org Prep Proc Int* **25**: 15
- [24] Saari WS, Fischer TE (1990) *Synthesis*: 453
- [25] Staudinger H, Kon N (1911) *Liebigs Ann Chem* **384**: 38
- [26] Grošelj U, Rečnik S, Svete J, Meden A, Stanovnik B (2002) *Tetrahedron: Asymmetry* **13**: 821
- [27] Sauers RR (1959) *J Am Chem Soc* **81**: 925
- [28] Grošelj U, Svete J, Stanovnik B: to be published
- [29] Stanovnik B, Svete J (2002) *Pyrazoles*. In: Naier R (ed) *Science of Synthesis, Houben-Weyl Methods of Organic Transformations*, vol 12, Thieme, Stuttgart, pp 15
- [30] Svete J, Golič L, Stanovnik B (1997) *J Heterocyclic Chem* **34**: 1115
- [31] Turk C, Svete J, Golobič A, Golič L, Stanovnik B (1998) *J Heterocyclic Chem* **35**: 513
- [32] Buchanan JG, Chacón-Fuertes ME, Wightman RH (1979) *J Chem Soc Perkin Trans 1*: 244
- [33] Šala M, Jakše R, Svete J, Golič L, Golobič A, Stanovnik B (2003) *Carbohydr Res* **338**: 2053